MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Organon & Co

Open

BrancheGesundheitswesen

12.15 2.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.79

Max

12.18

Schlüsselkennzahlen

By Trading Economics

Einkommen

-250M

109M

Verkäufe

10M

1.6B

KGV

Branchendurchschnitt

3.192

57.333

EPS

0.9

Dividendenrendite

10.54

Gewinnspanne

6.847

Angestellte

10,000

EBITDA

-64M

338M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+47.95% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

10.54%

2.63%

Nächstes Ergebnis

1. Mai 2025

Nächste Dividendenausschüttung

12. Juni 2025

Nächstes Ex-Dividendendatum

9. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.2B

2.9B

Vorheriger Eröffnungskurs

9.27

Vorheriger Schlusskurs

12.15

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Organon & Co Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Alphabet, Intel, AppFolio

24. Apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. Apr. 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. Apr. 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. Apr. 2025, 23:13 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. Apr. 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. Apr. 2025, 22:51 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. Apr. 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. Apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. Apr. 2025, 22:38 UTC

Market Talk
Ergebnisse

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. Apr. 2025, 22:24 UTC

Market Talk
Ergebnisse

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. Apr. 2025, 22:23 UTC

Ergebnisse

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. Apr. 2025, 22:09 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. Apr. 2025, 22:00 UTC

Market Talk
Ergebnisse

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. Apr. 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. Apr. 2025, 21:23 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. Apr. 2025, 21:04 UTC

Ergebnisse

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. Apr. 2025, 21:02 UTC

Ergebnisse

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer-Vergleich

Kursveränderung

Organon & Co Prognose

Kursziel

By TipRanks

47.95% Vorteil

12-Monats-Prognose

Durchschnitt 17 USD  47.95%

Hoch 24 USD

Tief 11 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Organon & Co – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

1

Buy

3

Halten

2

Sell

Technischer Score

By Trading Central

11.43 / 12.42Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.